Harmonization of the Upfront Osteosarcoma Treatment Paradigm for Adolescents and Young Adults.
J Adolesc Young Adult Oncol
; 2024 Jul 15.
Article
in En
| MEDLINE
| ID: mdl-39008434
ABSTRACT
Limited guidance exists on streamlining cancer therapy for adolescent and young adult (AYA) patients 15-39 years of age, as much of the current data are extrapolated from pediatric or adult counterparts and can differ significantly between the two care models. Harmonization of standard treatment approaches has the potential to improve outcomes and establish a foundation for the development of future clinical trials. We present our experience harmonizing treatment and supportive care regimens for AYA patients with osteosarcoma receiving treatment with methotrexate, doxorubicin, and cisplatin (MAP) therapy on the pediatric and adult sarcoma services at the Memorial Sloan Kettering Cancer Center.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Language:
En
Journal:
J Adolesc Young Adult Oncol
Year:
2024
Document type:
Article
Affiliation country:
United States